Biomarkers, Genomics, Proteomics, and Gene Regulation

Psoriasis Risk Genes of the Late Cornified Envelope-3 Group Are Distinctly Expressed Compared with Genes of Other *LCE* Groups

Judith G.M. Bergboer,* Geuranne S. Tjabringa,*
Marijke Kamsteeg,*
Ivonne M.J.J. van Vlijmen-Willems,*
Diana Rodijk-Olthuis,* Patrick A.M. Jansen,*
Jean-Yves Thuret,[†] Masashi Narita,[†]
Akemi Ishida-Yamamoto,[‡] Patrick L.J.M. Zeeuwen,*
and Joost Schalkwijk*

From the Department of Dermatology,* Radboud University
Nijmegen Medical Centre, Nijmegen Centre for Molecular Life
Sciences, Nijmegen, The Netherlands; Cancer Research UK,[†]
Cambridge Research Institute, Li Ka Shing Centre, Cambridge,
United Kingdom; and the Department of Dermatology,[‡]
Asabikawa Medical University, Asabikawa, Japan

Deletion of the late cornified envelope (*LCE*) genes *LCE3B* and *LCE3C* has recently been identified as a risk factor for psoriasis. Expression of 16 *LCE* genes of *LCE* groups 1, 2, 3, 5, and 6 was examined *in vivo* and *in vitro*. Quantitative PCR demonstrated that moderate to high *LCE* expression was largely confined to skin and a few oropharyngeal tissues. Genes of the *LCE3* group demonstrated increased expression in lesional psoriatic epidermis and were induced after superficial injury of normal skin, whereas expression of members of other *LCE* groups was down-regulated under these conditions. Immunohistochemistry and immunoelectron microscopy demonstrated that *LCE2* protein expression was restricted to the uppermost granular layer and the stratum corneum. Stimulation of *in vitro* reconstructed skin by several psoriasis-associated cytokines resulted in induction of *LCE3* members. The data suggest that *LCE* proteins of groups 1, 2, 5, and 6 are involved in normal skin barrier function, whereas *LCE3* genes encode proteins involved in barrier repair after injury or inflammation. These findings may provide clues to the mechanistic role of *LCE3B/C* deletion in psoriasis. (*Am J Pathol* 2011, 178:1470–1477; DOI: 10.1016/j.ajpath.2010.12.017)

Psoriasis is a common inflammatory skin disease caused by both genetic and environmental factors.^{1–3} A substantial number of psoriasis susceptibility loci has been identified that harbor genes involved in adaptive and innate immunity, such as *HLA-Cw6*, *IL12B*, *IL23R*, *TNFAIP3*, *TNIP1*, and the β -defensins.² Recently, a deletion of two members of the late cornified envelope genes, *LCE3B* and *LCE3C*, was identified as the first psoriasis risk factor with a putative role in skin barrier function.⁴ In support of this finding, an independent genome-wide association study of a large Chinese cohort found that single nucleotide polymorphisms in strong linkage disequilibrium with the *LCE3B/C* deletion are associated with psoriasis.⁵ This association has been widely replicated in cohorts of European and Asian origin.^{6,7}

The *LCE* genes are located on chromosome 1q21 in a region called the epidermal differentiation complex.⁸ This region is enriched for genes expressed during epidermal differentiation including loricrin, involucrin, filaggrin, the small proline-rich protein genes, and the *LCE* genes.^{9,10} With 18 members, the *LCE* gene family is divided into six groups, *LCE1* to *LCE6*, based on similarities of amino acid sequences, genomic organization, and patterns of expression.⁹

The role of the *LCE* proteins in epidermal biology has not been extensively studied. In mice, it was observed that members of the *Lce1* group are expressed rather late in epithelial development, where they are incorporated into the cornified envelope via cross-linking by

Supported in part by DPTE grant bgt.6739 and grant 114000084 from the Alternatives to Animal Experiments program of ZonMW; by the University of Cambridge, Cancer Research UK, Hutchison Whampoa, Ltd. (M.N.); and by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (A.I.-Y.).

P.L.J.M.Z. and J.S. contributed equally to this work.

Accepted for publication December 17, 2010.

Supplemental material for this article can be found at <http://ajp.amjpathol.org> or at doi: 10.1016/j.ajpath.2010.12.017.

Current address of J.-Y.T.: CEA, iBiTec-S, Gif-sur-Yvette, France.

Address reprint requests to Joost Schalkwijk, Ph.D., Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. E-mail: j.schalkwijk@ncmls.ru.nl.

transglutaminases.¹¹ Other investigators used quantitative PCR (qPCR) to demonstrate that the human *LCE1* and *LCE2* genes were primarily expressed in skin, whereas *LCE4* and *LCE5* gene expression was largely undetectable in the human tissues examined.⁹ *LCE3* gene expression was absent or variable at low levels in internal and external epithelia, although at that time the *LCE3B/C* deletion was not known, which may have affected these results. Studies in cultured keratinocytes demonstrated that *LCE2* expression is induced by Ca^{++} , whereas UVB irradiation induced expression of *LCE3E* and members of the *LCE1* and *LCE2* groups.⁹

In a previous study based on the observed *LCE3C* induction in lesional psoriatic skin and injured skin, a role for the *LCE3* genes in skin barrier repair was hypothesized.⁴ The present study sought to extend these studies, to find a possible clue to the mechanistic relationship between the *LCE3B/C* deletion and psoriasis. Expression of 16 *LCE* genes of the *LCE* groups 1, 2, 3, 5, and 6 was investigated *in vivo* and *in vitro* at the mRNA and the protein level. The results demonstrate that, compared with other *LCE* groups, members of the *LCE3* group are differently expressed, which suggests nonredundant functions that may be relevant for psoriasis.

Material and Methods

Human Tissues

Patients and healthy volunteers ($N = 6$ for all groups) were recruited by the Dermatology Clinic of Radboud University Nijmegen Medical Centre (Nijmegen, The Netherlands). All diagnoses were made by a dermatologist. The study was approved by the local medical ethical committee, "Commissie Mensgebonden Onderzoek Arnhem-Nijmegen," and conducted according to the Declaration of Helsinki principles. Written informed consent was obtained. Patients had moderate to severe plaque-type psoriasis. Biopsy specimens were taken from lesional and nonlesional skin ($N = 4$). For stratum corneum removal by tape stripping in healthy control individuals ($N = 5$), two areas on the lower back measuring 1×2 cm each were tape stripped until the surface glistened after repeated application and removal of adhesive tape (20 to 40 times). At 24 and 48 hours after tape stripping, 3-mm biopsy specimens were taken from the tape-stripped area and from healthy skin for RNA isolation and histologic analysis, respectively. Archival autopsy material from a large number of normal human tissues was obtained from the Department of Pathology (Radboud University Nijmegen Medical Centre).

Three-Dimensional Reconstructed Skin

Reconstructed skin was generated as described previously.¹² In brief, de-epidermized human dermis, 0.8 mm thick and 8 mm in diameter, was used as a scaffold for keratinocytes. Constructs were cultured submerged for 3 days in tissue culture inserts in a 24-well plate, and subsequently the medium level was lowered to enable air exposure to induce terminal differentiation. For analysis

of *LCE* expression during normal skin development, the constructs were cultured air-exposed for the indicated times. This cultured epidermis is negative for psoriasis-associated proteins such as cytokeratin 16, elafin, and human β -defensin.¹² At this point, a combination of pro-inflammatory cytokines [10 ng/mL of IL-1 α , 5 ng/mL of tumor necrosis factor- α (TNF- α), and 5 ng/mL of IL-6] or Th17 cytokines (100 ng/mL of IL-17 or 100 ng/mL of IL-22) was added for 72 hours ($N = 5$ per group) to induce cytokine-specific gene expression. Nine healthy donors of human keratinocytes were used.

Real-Time qPCR

Epidermal sheets from skin biopsy tissue or skin constructs were separated from the underlying dermis as described previously.¹³ The extracted and DNase I-treated RNA from these epidermal sheets was used for first-strand cDNA synthesis using a kit (iScript cDNA synthesis kit; Bio-Rad Laboratories, Inc., Hercules, CA) using 1 μg of RNA as input.¹⁴ The reverse transcriptase reaction products were used for qPCR amplification of genes of interest using a quantification system (MyiQ Single-Color Real-Time Detection System; Bio-Rad Laboratories, Inc.) and melting curve analysis as described previously.¹⁵ Expression of target genes was normalized to expression of the house-keeping gene human ribosomal phosphoprotein P0 (*RPLP0*) in the same sample. For analysis of *LCE1A*, *LCE1C*, *LCE1D* and *LCE1E*, and the complete *LCE2* group, primers were used as described previously.⁹ Primers for *LCE1B*, *LCE1F*, *LCE3A*, *LCE3C*, *LCE3D*, *LCE3E*, *LCE5A*, and *LCE6A* were designed, and PCR products were sequenced to check primer specificity. Primers (Biolegio BV, Nijmegen, The Netherlands) for qPCR were accepted only if their efficiency was between 90% and 110%. For *LCE3B* and *LCE4A*, none of the designed primer pairs met this criterion, and, therefore, these genes were not analyzed in this study. Primer sequences and efficiency are given in Table 1. Because the *LCE* primer pairs were not intron-spanning, each primer pair was also tested with input in which during cDNA synthesis no reverse transcriptase had been used. No specific product was found in any of these reactions. Relative mRNA expression levels were calculated using the $\Delta\Delta\text{-Ct}$ method.¹⁶ For graphic representation of mRNA data, all *in vivo* data are plotted relative to *LCE1A* expression in normal skin (Figures 1, 2A, and 3A) or uninvolved skin (Figure 2B). The *in vitro* data are plotted relative to expression of the same gene in the control condition (Figure 4).

LCE2 Antibody Production

A human pan-LCE2 antibody was raised in rabbits against the synthetic peptide RPRLFHRRRHQSPD. This peptide perfectly matches LCE2B, LCE2C, and LCE2D, and differs by one amino acid for LCE2A (fourth R→H in LCE2A). The antiserum was positively tested on recombinant human LCE2A from bacterial lysates at Western blot analysis (see Supplemental Figure S1 at <http://ajp.amjpathol.org>).

Table 1. Primers for qPCR

Gene	Forward primer	Reverse primer	E*
<i>LCE1A</i> [†]	5'-TGCAAGAGTGGCTGAGATGC-3'	5'-AGACAACACAGTTGGTGTCTCAGG-3'	2.18
<i>LCE1B</i>	5'-TGAGCCTAGAAGAACACAA-3'	5'-GAAGGAGAAGGAAGACGG-3'	1.94
<i>LCE1C</i> [†]	5'-GAATCCAGGACCGCAAACTG-3'	5'-TGGACCTGTGAGCCTCTCAG-3'	2.03
<i>LCE1D&E</i> [†]	5'-TGAATAGCTGAGAGGTTCCAGC-3'	5'-CAGCCATGGATCTGCAGAAG-3'	2.06
<i>LCE1F</i>	5'-CCACACCGAAGTGCC-3'	5'-GCTGCAGCAGGAAGAG-3'	1.83
<i>LCE2A</i> [†]	5'-GGACCTGTCCCAGAGTGATG-3'	5'-GATCCAGGATGGGCTCTTG-3'	2.10
<i>LCE2B</i> [†]	5'-GGTGTGACTAAACTCTGCCAGG-3'	5'-CACTGGGGCAGGCATTTA-3'	2.04
<i>LCE2C</i> [†]	5'-CTTGGGACTGAATGGCCAAG-3'	5'-GACTTGCAATGGGGTGTTAC-3'	1.91
<i>LCE2D</i> [†]	5'-CTGCAGAAGAGCTCTGGTACTG-3'	5'-CTCCATCAAGCACAAAGTTCTG-3'	2.15
<i>LCE3A</i>	5'-GAGTCACCACAGATGCC-3'	5'-CTTGCTGACCACTTCCC-3'	2.02
<i>LCE3C</i>	5'-CTGAGCCACCACAGGCATT-3'	5'-TGTTTCTCTCCAAAGATCACTTGTC-3'	2.03
<i>LCE3D</i>	5'-CCCATCTTGATGCATGAG-3'	5'-TGTGACATCCTGGACATCAG-3'	2.07
<i>LCE3E</i>	5'-CTGATGCTGAGACAAGCGATCTT-3'	5'-GATCCCCACAGGAAAACCT-3'	2.20
<i>LCE5A</i>	5'-CCCTCTTTATCCTGCC-3'	5'-ACAACACCTAGTTCTCCAA-3'	1.87
<i>LCE6A</i>	5'-AGAAGCAGCAATCTTGGA-3'	5'-CCTTTGGGAAGTGAATG-3'	2.05

*Efficiency as fold increase in fluorescence per PCR cycle.

[†]Primer was previously described by Jackson et al.⁹

Immunohistochemistry

Tissues or skin constructs were fixed in a buffered 4% formalin solution (Mallinckrodt Baker, Inc., Deventer, The Netherlands) for 4 hours and subsequently embedded in paraffin. Material was cut in 7- μ m sections and subsequently processed for staining using a kit (Vectastain ABC kit; Vector Laboratories, Inc., Burlingame, CA) as previously described.¹⁷ LCE2 staining was performed using the primary rabbit anti-human pan-LCE2 antibody and a goat anti-rabbit antibody as a secondary antibody (Vector Laboratories, Inc.).

Immunofluorescence Analysis

Skin biopsy specimens were fixed and cut as described (see "Immunohistochemistry"). Immunofluorescence analysis was performed as previously described¹⁸ using the rabbit anti-human pan-LCE2 antibody and a mouse anti-cathepsin V antibody (R&D Systems, Inc., Minneapolis, MN) as primary antibodies. The secondary reagents were Alexa Fluor 488 goat anti-rabbit IgG highly cross-absorbed and Alexa Fluor 594 goat anti-mouse IgG highly cross-absorbed (Molecular Probes, Inc., Eugene, OR). Nuclei were stained with DAPI (Dako-Cytomation A/S, Copenhagen, Denmark).

Immunoelectron Microscopy

Postembedding immunoelectron microscopy using resin (Lowicryl K11M; Chemische Werke Lowi GmbH, Waldkraiburg, Germany) was performed as described previously.¹⁹ The secondary antibody used for immunoelectron microscopy was 5 nm of gold-conjugated goat anti-rabbit IgG (BBInternational, Cardiff, UK).

Statistical Analysis

Data are given as mean (SD). Statistical analysis of qPCR data was performed on Δ Ct values using commercially available software (SPSS release 16.0; SPSS, Inc., Chi-

cago, IL). One-way analysis of variance, followed by Dunnett post hoc testing, and paired *t*-tests were performed. *P* < 0.05 was considered statistically significant.

Results

LCE Expression in Human Tissues

Because quantitative information about relative expression levels of the *LCE* gene family in human beings is limited,^{9,11} qPCR analysis was performed on a large panel of tissues including many epithelia. Expression was analyzed of all *LCE* genes except *LCE3B* and *LCE4A*, for which validation of specific primers failed. Because of high sequence similarities between *LCE1D* and *LCE1E*, these genes were analyzed together (Figure 1, D and E). Figure 1 shows the expression of the *LCE3* genes in a wide range of normal human tissues using the expression of *LCE1A* in skin as a reference (set at unity). The tissues originate from individuals homozygous for the *LCE3B/C* deletion; therefore, no *LCE3C* data are available. Gene expression data from the other *LCE* genes is shown in Supplemental Figure S2 (at <http://ajp.amjpathol.org>). Most samples demonstrated very low to undetectable *LCE* expression. Moderate expression was observed in trunk skin and some oral epithelia. High *LCE* gene expression was observed only in plantar skin.

Distinct Expression Patterns of LCE3 Genes in Normal and Psoriatic Skin

Figure 2A shows the mRNA expression of the various *LCE* genes as determined in epidermal sheets of normal skin and of lesional skin of patients with psoriasis (see Supplemental Table S1 at <http://ajp.amjpathol.org> for Δ Ct values and exact *P* values). Expression levels of the various *LCE* groups seemed to be groupwise regulated. All members of the *LCE* groups 1, 2, 5, and 6 were significantly down-regulated in psoriatic skin, whereas all genes of the *LCE3* group were barely present in normal skin and were significantly induced in psoriatic skin (for *LCE3C* only

Figure 1. Relative mRNA expression levels of *LCE3* genes in normal human tissues. Expression of target genes was normalized to that of *RPLP0*. For graphic representation, all values are expressed relative to *LCE1A* in skin, which was set at unity, to enable comparison of expression levels between tissues and genes (see Livak and Schmittgen¹⁶). Primer sequences and efficiency of amplification are given in Table 1. Expression of other *LCE* family members is shown in Supplemental Figure S1 (available at <http://ajp.amjpathol.org>). Normal human tissues are from a single individual, and data from normal skin are from 12 individuals. Data are given as mean (SD).

when present in the genome), as reported by others.²⁰ In four patients with psoriasis, *LCE* gene expression levels in uninvolved psoriatic skin were also investigated, and exhibited a similar expression pattern as observed in normal skin (Figure 2B and Supplemental Table S2 at <http://ajp.amjpathol.org>). To confirm the *LCE* mRNA expression data at the protein level, an antiserum directed against all *LCE2* members was used to stain paraffin sections of psoriatic and normal skin. Figure 2C shows that the pan-*LCE2* antibody stained the upper granular layer and stratum corneum of normal and lesional psori-

atic epidermis. No gross difference in staining intensity between normal and diseased skin was observed despite the decrease of mRNA expression observed for *LCE2* members (notably *LCE2B*) in psoriasis. Co-localization studies using immunofluorescence microscopy on normal skin sections demonstrated overlap between *LCE2* and cathepsin V expression (Figure 2D). Previous studies have shown that cathepsin V is present in the superficial granular layer and stratum corneum, where it is associated with corneodesmosomes.¹⁸ *LCE2* co-localized completely with cathepsin V in the granular layer, whereas expression in the stratum corneum partly co-localized. In the stratum corneum, *LCE2* is more broadly expressed. Immunoelectron microscopy analysis was performed to study the subcellular localization of the *LCE2* proteins, which were present in a diffuse cytoplasmic distribution in the cells of the granular layer. In the stratum corneum and upper granular layer, *LCE2* proteins were localized along the cornified envelopes (Figure 2E). *LCE2* expression in skin appendages was limited to nail, where expression was observed in the matrix, between the matrix and the proximal nail fold, in the proximal nail fold, and in the hyponychium (Figure 2F). No expression was observed in hair follicles or sweat glands (data not shown).

Skin Injury Induces Specific Expression of *LCE3* Genes

It has previously been demonstrated that expression of the *LCE3C* and *LCE3E* genes is induced after tape stripping of normal skin.⁴ Superficial skin injury in healthy volunteers leads to disruption of the skin barrier and induces epidermal activation as assessed by morphologic features, cell proliferation, and gene expression.²¹ qPCR analysis was used to investigate expression of all *LCE* genes before and after tape stripping of normal skin (Figure 3, and Supplemental Table S3 at <http://ajp.amjpathol.org>). The *LCE* genes of groups 1, 2, 5, and 6 were significantly down-regulated after tape stripping, whereas the *LCE3* genes were significantly up-regulated. This pattern of groupwise induction and down-regulation was similar to that in normal versus psoriatic skin (Figure 2A). mRNA data were confirmed at the protein level for *LCE2*. Figure 3B shows that before tape stripping, *LCE2* was detected in the uppermost layer of the stratum granulosum and in the entire orthokeratotic stratum corneum. Forty-eight hours after tape stripping, *LCE2* protein was completely absent in the granular layer and in the parakeratotic stratum corneum.

LCE Gene Expression in Stratifying Epidermis in a Reconstructed Skin Model

To examine the dynamics of *LCE* gene expression during the process of epidermal stratification, reconstructed skin on de-epidermized dermis was used, as described previously.²² The mRNA data (see Supplemental Figure S3A and Supplemental Table S4 at <http://ajp.amjpathol.org>) demonstrate that expression of the *LCE* genes was very

Figure 2. LCE expression in normal and psoriatic skin. Relative *LCE* gene mRNA expression levels in epidermal sheets from healthy control individuals (NS) and patients with psoriasis (PS) ($N = 6$) (A) and uninvolved and involved skin from patients with psoriasis ($N = 4$) (B). All values are expressed relative to *LCE1A* in normal or uninvolved skin. $*P < 0.05$ compared with normal or uninvolved skin [mean (SD)]. C: Immunohistochemical staining with the pan-LCE2 antibody on normal skin (NS) and lesional psoriatic skin (PS). Scale bar = 100 μm . D: Colocalization (merged yellow signal) of LCE2 (green) and cathepsin V (red) in the upper granular layer of normal skin. Scale bar = 50 μm . E: Immunoelectron microscopy. LCE2 labels (arrowheads) are associated with the cornified envelope in the stratum granulosum. D, desmosome; KHG, keratohyalin granule. Scale bar = 50 μm . F: Immunohistochemical staining for the LCE2 group in nail. Scale bar = 50 μm .

low at day 0 (mean Ct-value, 31). At this time, the cells are still present as an undifferentiated layer of a few cells. After 3 days of air exposure, expression of all *LCE* genes except *LCE3A* and *LCE5A* was highly induced. The *LCE* expression levels continued to rise until day 6, then stabilized until day 15 of the air-exposure phase. The qPCR results for *LCE2* were confirmed at the protein level (Figure S3B). *LCE2* proteins were not expressed in the skin construct at day 0; however, from day 3 onward, expression gradually emerged in the stratum granulosum, and later *LCE2* proteins were also present in the stratum corneum. The expression data for reconstructed skin, at both the mRNA and

protein levels (for *LCE2*), were similar to those observed in normal human skin (Figure 2B), which indicates that this is a suitable model for study of *LCE* biology *in vitro*. In this model, higher expression of *LCE3D* and *LCE3E* and lower expression of *LCE5A* was observed compared with expression levels of these genes in normal skin.

Cytokine Induction of *LCE* Gene Expression in a Reconstructed Skin Model

A recently developed *in vitro* psoriatic skin model was used to examine disease-specific keratinocyte gene ex-

Figure 3. LCE expression before and after tape stripping in normal skin. A: Relative mRNA expression levels of *LCE* genes in epidermal sheets of healthy control individuals before and after tape stripping (TS) ($N = 5$). All values were expressed relative to *LCE1A* in skin to enable comparison of expression levels between genes. $*P < 0.05$ compared with before tape stripping [mean (SD)]. B: Immunohistochemical staining with the pan-LCE2 antibody on sections of normal skin before tape stripping (upper and middle panels), before enlarged (middle panel), and 48 hours after tape stripping (lower panel). Each illustration is representative of data for five different individuals. Scale bar = 50 μm .

Figure 4. Cytokine-induced *LCE* mRNA expression in reconstructed skin. Relative mRNA expression levels of *LCE* genes in epidermal sheets from skin constructs after stimulation with different cytokine combinations ($N = 5$ per group): 10 ng/mL of IL-1 α , 5 ng/mL of TNF- α , and 5 ng/mL of IL-6 or 100 ng/mL of IL-17 or 100 ng/mL of IL-22. Values for each gene were expressed relative to the control culture condition, which was set at unity. It is not possible to compare expression levels between genes. $*P < 0.05$ compared with control condition [mean (SD)].

pression levels.¹² This model was used to study the effect of proinflammatory cytokines associated with psoriasis on expression of *LCE* genes. A combination of psoriasis-associated cytokines TNF- α , IL-1 α , and IL-6 significantly induced expression of the *LCE3* genes, whereas this combination and the Th17 cytokine IL-22 significantly down-regulated expression of *LCE1B* (Figure 4 and Supplemental Table S5 at <http://ajp.amjpathol.org>). IL-17 and IL-22 demonstrated nonsignificant up-regulation of the *LCE3* genes. The investigated cytokine combinations did not significantly affect expression of other *LCE* members.

Discussion

Herein is reported a comprehensive study on the expression of human *LCE* genes *in vivo* and *in vitro*. The highest expression of all *LCE* genes was observed in skin, and moderate expression in some oral epithelia. Very low to undetectable expression was observed for all *LCE* genes in most samples from a broad panel of tissues including many epithelia. Of 16 investigated *LCE* genes, only expression of the *LCE3* group members was significantly induced in psoriatic skin, whereas genes from the other *LCE* groups were significantly down-regulated. Similar groupwise expression patterns were observed after superficial injury of normal skin by tape stripping. Localization studies demonstrated that the *LCE2* proteins are expressed in the uppermost layer of the stratum granulosum on cornified envelopes. Stimulation of *in vitro* reconstructed skin with psoriasis-associated cytokines demonstrated induction of *LCE3* gene expression. This *in*

vitro model also demonstrated that during the process of epidermal stratification, *LCE* gene and protein expression begins at the moment of stratum corneum formation.

Analysis of tissue expression suggests that all *LCE* genes are likely involved in skin-specific processes. The data presented herein confirmed the results of previous studies of *LCE1*, *LCE2*, and *LCE5* expression. One study, however, demonstrated that *LCE3* genes were primarily expressed in esophagus and tongue, and were barely present in skin.¹¹ This may be because only normal skin was studied, in which *LCE3* expression is low. The *LCE2* proteins are localized in the superficial cells of the stratum granulosum and in premature cornified envelopes, resembling involucrin staining in normal skin.²³ In mouse embryos, similar localizations were observed for *Lce1*.¹¹ *LCE2* is also present in the nail unit, at similar locations as involucrin, filaggrin, and transglutaminase 3,²⁴ which suggests that *LCE2* is not only involved in terminal differentiation in the epidermis but also in the nail unit. From *in vitro* data in stratifying epidermis, it was observed that *LCE* expression begins at the moment of stratum corneum formation, which is similar to loricrin expression in a previous study.²² Together these results strengthen previous observations that *LCE* proteins are expressed late and are finally localized in the stratum corneum as part of the cornified envelope.¹¹

The present study demonstrated that induction of *LCE3* gene expression observed in lesional psoriatic epidermis can be mimicked by adding a combination of TNF- α , IL-1 α , and IL-6 to the reconstructed skin model. In addition, the Th17 cytokines seem to have an effect on

Figure 5. Tentative model of psoriasis based on genetic and cell biological data. It was proposed that minor trauma such as by mechanical stimuli or subclinical infection will breach the skin barrier and induce cell damage, which subsequently causes activation of keratinocytes. Keratinocytes will respond to superficial injury by innate immune responses such as activation of nuclear factor κ B signaling and secretion of chemokines, cytokines, and β -defensins. This has been well documented in *in vivo* (tape stripping) and *in vitro* models. Skin barrier disruption will activate repair mechanisms such as up-regulation of normal constituents (involucrin and transglutaminase-1) and induce expression of *LCE3* genes (present study). The speed and quality of the temporary skin barrier may depend on the genotype for the *LCE3B/C* deletion. Individuals harboring a deleted allele may be subject to increased penetration of environmental or microbial antigens. The low-grade inflammation caused by keratinocyte activation will attract immunocompetent cells (T cells and dendritic cells) to the skin and could lead to activation of adaptive immunity in genetically predisposed individuals that responds to unidentified antigens that have penetrated the skin. The ensuing immune response characterized by secretion of Th1 and Th17 cytokines will in turn cause activation of keratinocytes, resulting in a vicious cycle and chronicity of inflammation.

LCE3 expression; IL-22 demonstrated a trend toward induction, especially of *LCE3A*. The effects on *LCE3D* and *LCE3E* gene expression are smaller. It could be that the basal expression levels of these genes in the reconstructed skin model are higher in the control situation than in normal skin; thus, induction of gene expression is more difficult to demonstrate. Previous *in vitro* studies used submerged keratinocyte cultures in which *LCE2* gene expression was induced by adding Ca^{++} -rich medium.⁹ UVB irradiation caused induction of the *LCE1* and *LCE2* groups and of *LCE3E*. Expression of other *LCE* genes remained low in both situations. These results do not show the same groupwise expression as observed in the present study. This might be caused by the use of submerged cultures in which the basal expression levels of the *LCE* genes are very low (data not shown).

Deletion of *LCE3B* and *LCE3C* is a widely replicated risk factor for psoriasis.^{4–7} Although the associated odds ratio is modest (1.21 in a recent meta-analysis⁷) compared with that of *HLA-Cw6* (2.8 according to another meta-analysis²⁵), the high prevalence of the deletion in patients with psoriasis results in a considerable population-associated risk (21%).⁴ Its reported epistasis with *HLA-Cw6* in at least some white populations makes it a major risk factor for psoriasis.⁷ Inasmuch as all *LCE* genes are similar and would be predicted to exert similar functions, the question arises as to why deletion of 2 of 18 quite similar *LCE* genes could have a role in the etiology of psoriasis. Herein it was demonstrated that four of the five *LCE3* genes are differently expressed compared with other *LCE* groups. It was interpreted that *LCE3* members may function as barrier repair proteins whose expression is driven by proinflammatory cytokines, whereas other *LCE* proteins have a constitutive role in barrier function of normal skin. Heterozygous or homozygous deletion of *LCE3B* and *LCE3C*, which is observed in greater than 90% of patients with psoriasis, could potentially affect skin barrier properties (compared with the homozygous ancestral status of two intact chromosomes), in particular under conditions of stress.⁷ Thus, concerning the relevance for psoriasis, there is deletion of two of five *LCE3* genes rather than two of 18 *LCE* genes. Because *LCE3B* and *LCE3C* are expressed at low levels, if at all, in normal skin, the situation is different from the filaggrin (*FLG*) gene and atopic dermatitis.²⁶ In atopic dermatitis, it has been suggested that a slightly leaky skin barrier could enable penetration of environmental allergens and would favor development of atopy.²⁷ For *LCE3B* and *LCE3C*, expression is induced only after barrier disruption. Although 18 *LCE* genes are present on the genome, only five genes from this family seem to have a function after skin barrier disruption or inflammation. It was hypothesized that because of deletion of *LCE3B* and *LCE3C*, in combination with other unknown factors, an incomplete skin barrier repair response could occur after minor skin injury. It is speculated that the presence of only the *LCE3A*, *LCE3D*, and *LCE3E* proteins is not sufficient for a complete barrier repair response. A consequence could be increased permeability for environmental stimuli (eg, microbial components), leading to activation of innate immune mechanisms and subsequent recognition by the adaptive

immune system in predisposed (eg, *HLA-Cw6*+) individuals (Figure 5). This is a testable hypothesis that merits further investigation.

Acknowledgments

We thank the volunteers who participated in this study and Ms. Noriko Takashita for assisting with the immunoelectron microscopy experiments.

References

1. Bowcock AM, Krueger JG: Getting under the skin: the immunogenetics of psoriasis. *Nat Rev Immunol* 2005, 5:699–711
2. Nestle FO, Kaplan DH, Barker J: Psoriasis. *N Engl J Med* 2009, 361:496–509
3. Schon MP, Boehncke WH: Psoriasis. *N Engl J Med* 2005, 352:1899–1912
4. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, Giardina E, Stuart PE, Nair R, Helms C, Escaramis G, Ballana E, Martin-Ezquerria G, den Heijer MD, Kamsteeg M, Joosten I, Eichler EE, Lazaro C, Pujol RM, Armengol L, Abecasis G, Elder JT, Novelli G, Armour JA, Kwok PY, Bowcock A, Schalkwijk J, Estivill X: Deletion of the late cornified envelope *LCE3B* and *LCE3C* genes as a susceptibility factor for psoriasis. *Nat Genet* 2009, 41:211–215
5. Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, Zhang FR, Zhang C, Du WH, Pu XM, Li H, Xiao FL, Wang ZX, Cui Y, Hao F, Zheng J, Yang XQ, Cheng H, He CD, Liu XM, Xu LM, Zheng HF, Zhang SM, Zhang JZ, Wang HY, Cheng YL, Ji BH, Fang QY, Li YZ, Zhou FS, Han JW, Quan C, Chen B, Liu JL, Lin D, Fan L, Zhang AP, Liu SX, Yang CJ, Wang PG, Zhou WM, Lin GS, Wu WD, Fan X, Gao M, Yang BQ, Lu WS, Zhang Z, Zhu KJ, Shen SK, Li M, Zhang XY, Cao TT, Ren W, Zhang X, He J, Tang XF, Lu S, Yang JQ, Zhang L, Wang DN, Yuan F, Yin XY, Huang HJ, Wang HF, Lin XY, Liu JJ: Psoriasis genome-wide association study identifies susceptibility variants within *LCE* gene cluster at 1q21. *Nat Genet* 2009, 41:205–210
6. Huffmeier U, Bergboer JG, Becker T, Armour JA, Traupe H, Estivill X, Riveira-Munoz E, Mossner R, Reich K, Kurrat W, Wienker TF, Schalkwijk J, Zeeuwen PL, Reis A: Replication of *LCE3C-LCE3B* CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. *J Invest Dermatol* 2010, 130:979–984
7. Riveira-Munoz E, He SM, Escaramis G, Stuart PE, Huffmeier U, Lee C, Kirby B, Oka A, Giardina E, Liao W, Bergboer J, Kainu K, de CR, Munkhbat B, Zeeuwen PL, Armour JA, Poon A, Mabuchi T, Ozawa A, Zawirska A, Burden AD, Barker JN, Capon F, Traupe H, Sun LD, Cui Y, Yin XY, Chen G, Lim HW, Nair RP, Voorhees JJ, Tejasvi T, Pujol R, Munkhtuvshin N, Fischer J, Kere J, Schalkwijk J, Bowcock A, Kwok PY, Novelli G, Inoko H, Ryan AW, Trembath RC, Reis A, Zhang XJ, Elder JT, Estivill X: Meta-analysis confirms the *LCE3C-LCE3B* deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with *HLA-Cw6*. *J Invest Dermatol*, doi: 10.1038/jid.2010.350.
8. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A: Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. *J Invest Dermatol* 1996, 106: 989–992
9. Jackson B, Tilli CM, Hardman MJ, Avilion AA, MacLeod MC, Ashcroft GS, Byrne C: Late cornified envelope family in differentiating epithelia-response to calcium and ultraviolet irradiation. *J Invest Dermatol* 2005, 124:1062–1070
10. Zhao XP, Elder JT: Positional cloning of novel skin-specific genes from the human epidermal differentiation complex. *Genomics* 1997, 45:250–258
11. Marshall D, Hardman MJ, Nield KM, Byrne C: Differentially expressed late constituents of the epidermal cornified envelope. *Proc Natl Acad Sci USA* 2001, 98:13031–13036
12. Tjabringa G, Bergers M, van Rens D, de Boer R, Lamme E, Schalkwijk J: Development and validation of human psoriatic skin equivalents. *Am J Pathol* 2008, 173:815–823

13. van Ruissen F, Jansen BJ, de Jongh GJ, Zeeuwen PL, Schalkwijk J: A partial transcriptome of human epidermis. *Genomics* 2002, 79:671–678
14. de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, Dogan A, Hiemstra PS, van de Kerkhof PC, Schalkwijk J: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. *J Invest Dermatol* 2005, 125:1163–1173
15. Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J, van Erp PE: Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. *J Invest Dermatol* 2005, 124:373–383
16. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001, 25:402–408
17. Le M, Schalkwijk J, Siegenthaler G, van de Kerkhof PC, Veerkamp JH, van der Valk PG: Changes in keratinocyte differentiation following mild irritation by sodium dodecylsulphate. *Arch Dermatol Res* 1996, 288:684–690
18. Zeeuwen PL, Ishida-Yamamoto A, van Vlijmen-Willems IM, Cheng T, Bergers M, Iizuka H, Schalkwijk J: Colocalization of cystatin M/E and cathepsin V in lamellar granules and corneodesmosomes suggests a functional role in epidermal differentiation. *J Invest Dermatol* 2007, 127:120–128
19. Ishida-Yamamoto A, Simon M, Kishibe M, Miyauchi Y, Takahashi H, Yoshida S, O'Brien TJ, Serre G, Iizuka H: Epidermal lamellar granules transport different cargoes as distinct aggregates. *J Invest Dermatol* 2004, 122:1137–1144
20. Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A, Nograles KE, Shemer A, Fuentes-Duculan J, Cardinale I, Lin P, Bergman R, Bowcock AM, Krueger JG: Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. *J Allergy Clin Immunol* 2009, 124:1235–1244
21. Van Duijnhoven-Avontuur WM, Alkemade JA, Schalkwijk J, Mier PD, van der Valk PG: The inflammatory and proliferative response of normal skin in a model for acute chemical injury: ornithine decarboxylase induction as a common feature in various models for acute skin injury. *Br J Dermatol* 1994, 130:725–730
22. Cheng T, Tjabringa GS, van Vlijmen-Willems IM, Hitomi K, van Erp PE, Schalkwijk J, Zeeuwen PL: The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis. *Br J Dermatol* 2009, 161:253–264
23. Ishida-Yamamoto A, Eady RA, Watt FM, Roop DR, Hohl D, Iizuka H: Immunoelectron microscopic analysis of cornified cell envelope formation in normal and psoriatic epidermis. *J Histochem Cytochem* 1996, 44:167–175
24. Cheng T, van Vlijmen-Willems IM, Hitomi K, Pasch MC, van Erp PE, Schalkwijk J, Zeeuwen PL: Colocalization of cystatin M/E and its target proteases suggests a role in terminal differentiation of human hair follicle and nail. *J Invest Dermatol* 2009, 129:1232–1242
25. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR: Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. *Nat Genet* 2009, 41:199–204
26. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El HB, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* 2006, 38:441–446
27. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ: Epidermal barrier dysfunction in atopic dermatitis. *J Invest Dermatol* 2009, 129:1892–1908